Idiopathic Hypersomnia Treatment Market to Surpass US$ 429.0 Million by 2027 - Coherent Market Insights

Global Idiopathic Hypersomnia Treatment Market, by Drug Class (Stimulant Medications, Non-stimulant wake-promoting Medications, and Sodium Oxybate), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 242.4 million in 2020 and is expected to exhibit a CAGR of 8.7% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The increasing cases of idiopathic hypersomnia and rise in awareness for this rare disease are some of the major factors that are expected to drive growth of the global idiopathic hypersomnia treatment market. For instance, in November 2016, The Hypersomnia Foundation, Inc., a leading hypersomnia advocacy and awareness non-profit organization, joined GivingTuesday Campaign to raise awareness and funding for research, restricted to study idiopathic hypersomnia (IH)

Idiopathic hypersomnia is a type of hypersomnia, a neurological sleep disorder that can affect many aspects of a person's life such as daily work routine, and behavioral changes. Symptoms of idiopathic hypersomnia disease often begin during adolescence and young adulthood and develop over weeks to months. Patients with idiopathic hypersomnia have difficulty in staying awake and alert during the day (chronic excessive daytime sleepiness, or EDS). Moreover, patients may fall asleep unintentionally or at inappropriate times, interfering with daily functioning. There is no approved drug for the treatment of idiopathic hypersomnia. However, there are drugs such as sodium oxybate available for the symptomatic relief and can be used for off-label treatment of idiopathic hypersomnia.

Global Idiopathic Hypersomnia Treatment Market– Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic has affected various industries globally. Supply of key raw materials for producing drugs has been severely disrupted due to the forced quarantine, and lack of labor and raw materials. As the link between regional warehouses is not smooth, the transportation of raw materials between regions cannot be carried out successfully. This shortage of raw materials and components have affected the supply chain of the global idiopathic hypersomnia treatment market. Quarantine, traveling constraints, and social distancing measures are likely to lead to a steep decline in business and consumer spending until the end of the 2020. Moreover, due to the increasing prevalence of COVID-19, key players operating in the idiopathic hypersomnia treatment market are focusing on research and development of novel products to support and combat the effect of COVID-19. Ongoing clinical trials for idiopathic hypersomnia drugs have been halted in initial quarters of 2020, which has impacted new drug development and research activities.

Browse 26 Market Data Tables and 29 Figures spread through 180 Pages and in-depth TOC on “Idiopathic Hypersomnia Treatment”- Global Forecast to 2027, by Drug Class (Stimulant Medications, Non-stimulant wake-promoting Medications, and Sodium Oxybate), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),

To know the latest trends and insights prevalent in the global idiopathic hypersomnia treatment market, click the link below:

https://www.coherentmarketinsights.com/market-insight/idiopathic-hypersomnia-treatment-market-4306

Furthermore, product pipeline for idiopathic hypersomnia treatment is also fueling growth of the global idiopathic hypersomnia treatment market. For instance, in December 2018, American Academy of Sleep Medicine, and Lynn Marie Trotti, Emory University collaboratively initiated the phase 2 study of Modafinil Versus Amphetamines for the treatment of narcolepsy type 2 and idiopathic hypersomnia.  

Key Takeaways of the Global Idiopathic Hypersomnia Treatment Market:

• The global idiopathic hypersomnia treatment market is expected to exhibit a CAGR of 8.7% during the forecast period, owing to rising number of cases of lifestyle diseases such as anxiety, depression, and increasing diagnosis rate of rare diseases due to advanced technologies. For instance, according one study done by Chastang J, et al. & published in iMedPub Journals, in 2016, more than 6% of population was affected by anxiety & anxiety related disorder in France.
• Among drug class, stimulant medications segment is estimated to hold a dominant position in the global idiopathic hypersomnia treatment market in 2020, owing to rise in demand of stimulant medications due to higher efficacy of drugs of these class for the treatment of hypersomnia. For instance, there are various approved stimulants in the global market for sleeping disorders such as stimulants approved for the treatment of sleepiness in narcolepsy include dextroamphetamine (e.g., Dexedrine) and methylphenidate (e.g., Ritalin).
• In terms of distribution channel, hospital pharmacies segment dominated the global idiopathic hypersomnia treatment market in 2019. Higher number of hospital admissions for the treatment of anxiety, panic disorders, and early diagnosis of rare diseases by specialty clinics. For instance, according to United Kingdom National Health Service (NHS) data, there has been a 28% increase in the number of hospital admissions for stress and anxiety in the past decade in the U.K.
• Among regions, North America is estimated to hold largest market share in the global idiopathic hypersomnia treatment market in 2020, owing to increasing awareness campaigns for rare diseases such as idiopathic hypersomnia, favorable reimbursement scenario, increasing healthcare expenditure, and ongoing clinical trials in the region. For instance, an analysis of the Hypersomnia Foundation’s International Patient Registry at CoRDS (Coordination of Rare Diseases at Sanford) was initiated in March 2015 for people with idiopathic hypersomnia and other related sleep disorders such as narcolepsy and Kleine-Levin syndrome.
• Key players operating in the global idiopathic hypersomnia treatment market include Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Inc., BIOPROJET, Avadel Pharmaceuticals, Plc. GlaxoSmithKline plc, Pfizer Inc., Theranexus, Fisher & Paykel Healthcare Limited, Drive DeVilbiss Healthcare LLC, and Merck & Co. Inc.